BioSyent Announces Quarterly Dividend for 2024
BioSyent Announces Quarterly Dividend for 2024
BioSyent Inc. (“BioSyent”, “the Company”, TSX Venture: RX) has declared a quarterly dividend of $0.045 per common share, payable in Canadian Dollars. This dividend will be distributed to shareholders of record at the close of business soon. This announcement reflects the company’s ongoing commitment to returning value to its investors.
Quarterly Dividend Details
The declared dividend is consistent with the second quarter payment, indicating stability in BioSyent’s financial performance. This dividend qualifies as an 'eligible dividend' for Canadian income tax purposes, which may enhance its attractiveness to investors. The Board of Directors retains discretion over future dividends, which allows them to adapt to changing business conditions.
Dividend Payment Schedule
The dividend payment is set for a specific date, ensuring that shareholders receive their returns in a timely manner. The company continues to demonstrate a solid dividend strategy, underscoring its strong economic foundations and profitable growth.
About BioSyent Inc.
BioSyent, listed on the TSX Venture Exchange under the trading symbol “RX”, is a profitable specialty pharmaceutical entity dedicated to the acquisition and development of innovative healthcare products. The company’s focus on in-licensing successful pharmaceutical products establishes its commitment to enhancing patient lives through effective medical solutions.
Company Growth and Focus
BioSyent has positioned itself as a growth-oriented company by marketing its products through various business units directed toward community, specialty, and international markets. This diversified approach enables BioSyent to better support healthcare professionals and effectively meet patient needs.
Current Shares and Financial Information
The Company has a substantial number of common shares outstanding, standing at 11,586,914, which reflects its active engagement in the market. This transparency is part of BioSyent’s commitment to keeping its shareholders informed about its financial standing.
Investor Relations
For those interested in real-time market quotes and additional financial insights regarding BioSyent, the company encourages investors to consult relevant financial platforms. These resources play a crucial role in keeping shareholders aware of the company’s market performance.
Contact Information
For direct inquiries or further assistance, investors can reach out to Mr. René C. Goehrum, President and CEO of BioSyent Inc. Communication can be done through email at investors@biosyent.com or by phone at 905-206-0013. BioSyent also maintains an informative web presence through its corporate website.
Frequently Asked Questions
What is the declared dividend amount for Q3 2024?
The declared dividend for Q3 2024 is $0.045 per common share.
When is the dividend payment scheduled?
The payment is scheduled for a specific date, subject to the record date for shareholders.
What is the focus of BioSyent Inc.?
BioSyent focuses on in-licensing and acquiring innovative pharmaceutical and healthcare products.
How many common shares does BioSyent currently have outstanding?
BioSyent currently has 11,586,914 common shares outstanding.
Who can I contact for more information about BioSyent?
For more information, you can contact Mr. René C. Goehrum, the President and CEO, via email or phone.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
Disclaimer: The content of this article is solely for general informational purposes only; it does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice; the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. The author's interpretation of publicly available data shapes the opinions presented here; as a result, they should not be taken as advice to purchase, sell, or hold any securities mentioned or any other investments. The author does not guarantee the accuracy, completeness, or timeliness of any material, providing it "as is." Information and market conditions may change; past performance is not indicative of future outcomes. If any of the material offered here is inaccurate, please contact us for corrections.
Related Articles
- Innovative Solutions for Caregivers in Breast Cancer Support
- Celebrating the Importance of Midwife Care for Families
- Positive Trends Anticipated for United Continental's Earnings
- Bascom Group Launches CRES for Enhanced Asset Management
- Challenges Ahead for Tesla in Autonomous Vehicle Leadership
- Wells Fargo Updates Price Target for Chart Industries Stock
- TD Cowen Adjusts Price Target for ULTA Beauty Amid Competition
- Concerns Over Stellantis Dividend Spark Stock Decline Amid Downgrade
- Steel Wire Market Growth and Innovations for Future Prospects
- AI-Powered RIO Security Towers Transform Public Safety Efforts
Recent Articles
- Cellectis Unveils Innovative SMART DUAL CAR T-cell Therapy
- Freddie Mac Releases July 2024 Monthly Volume Summary
- LuxUrban Hotels Inc. Faces Compliance Challenge with Nasdaq
- Icahn Enterprises Faces Share Dilution Concerns
- Neil Clifford's Journey: From Car Sales to Footwear Success
- Financial Warnings from The Ramsey Show on Luxury Purchases
- Multifunctional Food Ingredients Market to Reach $36.72 Billion
- XWELL Partners with Priority Pass for Enhanced Traveler Wellness
- Healthcare Realty Trust Expands Joint Venture with KKR
- California Water Service Group Recognized as Top Workplace
- Farmer Bros. Co. to Announce Fourth Quarter Financial Results
- Archrock Completes $700 Million Senior Notes Offering
- ClearPoint Neuro Completes Early Repayment of $10 Million Note
- Jason McDonell Named New CEO of Leslie’s, Inc.
- Trinity Biotech Expands TrinScreen HIV Orders and Revenue Outlook
- LifeVantage Appoints Rajendran Anbalagan to Board
- Notable Labs Announces New CEO and Future Plans
- O-I Glass to Showcase Insights at UBS Global Materials Conference
- Longeveron to Present Exciting Developments at Investment Conference
- Sana Biotechnology Welcomes Dhaval Patel as New CSO
- LifeMD to Showcase Innovations at Upcoming Investor Conferences
- IO Biotech to Present at Upcoming Healthcare Conferences
- Varonis Systems to Showcase Innovations at Investor Conference
- Flywire Corporation to Participate in Key Investor Conferences
- ORIC Pharmaceuticals Announces Participation in Investor Events
- Aura Biosciences Presents Phase 2 Data on Bel-sar Treatment
- Avista Announces Leadership Transition as CEO Dennis Vermillion Retires
- Structure Therapeutics Engages with Investors at Key Conferences
- Calavo Growers Inc. to Announce Q3 Financial Results
- DSS, Inc. Appoints Jason Grady as Interim CEO
- Shuttle Pharmaceuticals Faces Nasdaq Listing Non-Compliance
- Pineapple Energy Reports on Recent Financial Performance Insights
- DeNube Launches Revolutionary Decentralized GPU Cloud Network
- Massey Ferguson 9S Series Tractor: A Game Changer for Farmers
- Nvidia Earnings: An Underpriced Risk for Investors
- Oroco Resource Corp. PEA Update Webinar and Report Filing
- McEwen Mining Partners for 100% Renewable Energy in Copper Project
- Tech Stocks Struggle as Nvidia Earnings Approach
- Harvard Apparatus Secures $5 Million for Clinical Advancements
- Understanding Medical Properties Trust's Dividend Cut
- Understanding Roth IRAs and the Social Security Tax
- Understanding the Recent Decline of Icahn Enterprises
- Industrial Food Blanchers Market to Reach USD 574 Billion
- Brady Corporation to Host Earnings Conference Call
- Union Claims Against Chipotle Highlight Labor Rights Issues
- Nvidia Prepares for Second Quarter Earnings Report
- Ergodyne's Advanced Tool Tethering Solutions Announced
- Associa Canada Achieves Great Place To Work Certification
- Kingswood Capital Partners Closes $8 Million IPO for WORK MedTech
- Pixalate's Q2 2024 Fraudulent CTV Bundle IDs Report